# Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Study · id `cardio:ct-nct00117936` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT00117936](<https://clinicaltrials.gov/study/NCT00117936>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT00117936

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT00117936. Randomized; double masking; primary purpose treatment. Start 2027-09-01 (anticipated); primary completion 2029-11-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT00117936, source copy `cardio:ctgov-nct00117936-2026-08-19`, retrieved 2026-10-26)
- Planned start: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT00117936, source copy `cardio:ctgov-nct00117936-2026-08-19`, retrieved 2026-10-26)
- Primary completion: 2029-11-15 (anticipated) (ClinicalTrials.gov record NCT00117936, source copy `cardio:ctgov-nct00117936-2026-08-19`, retrieved 2026-10-26)
- Completion: 2030-06-15 (anticipated) (ClinicalTrials.gov record NCT00117936, source copy `cardio:ctgov-nct00117936-2026-08-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct00117936-2026-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
- Condition: Coronary Disease
- Condition: Coronary Heart Disease
- Condition: Myocardial Ischemia
- Condition: Coronary Arteriosclerosis
- Intervention (Combination product): Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose
- Intervention (Combination product): Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
- Intervention (Combination product): Placebo
- Lead sponsor: Venturis Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 452d602749a2a86760126516f579d1259db8774d17688d355d47d5809a52f51d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
